ConjuGon: to Present at Global Biotech Forum

Contact Sal Braico at (608)
441-2890 or with questions.


March 29, 2004 Madison, WI-ConjuGonR announces today that it was
selected to present at the Sachs-Bloomberg Global Biotech Forum for
Investing & Partnering. The Forum, which will be held April 1-2, 2004,
in Boston, brings together promising biotechnology companies, leading
investors and pharmaceutical companies.

“We are anticipating that ConjuGon’s vital technology will be of great
interest at the conference,” said CEO Christopher Price, who became
ConjuGon’s CEO in February 2004. Price has more than 20 years of
experience in biotechnology companies.

ConjuGon has raised more than $1.1 million in seed capital, including
$700,000 from angel investors, and $290,000 in economic development
loans from the Madison Development Corporation and the Wisconsin
Department of Commerce. The company has also been awarded a $100,000
Small Business Innovation Research (SBIR) Phase I grant from the
National Science Foundation.

ConjuGon is developing fundamentally new technologies to combat the
growing epidemic of antibiotic-resistant bacteria. Antibiotic resistance
is a medical crisis, globally responsible for hundreds of thousands of
deaths each year. ConjuGon’s core technology is a new way to kill
unwanted and even multi-drug resistant bacteria. The company, which has
an experienced staff of six, is located in the MG&E Innovation Center in